PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Global Drug Forecast and Market Analysis to 2022

Description: PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Global Drug Forecast and Market Analysis to 2022

Summary

Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people are infected with HBV worldwide, with roughly 600,000 people dying each year from HBV-related liver diseases. While the arrival of recombinant HBsAg vaccines has greatly reduced disease burden over the past two decades, questions surrounding vaccine uptake and effectiveness in adults, particularly in niche patient populations, still remain. GlobalData expects that the growing popularity of pediatric combination vaccines, along with the arrival of vaccines that achieve higher seroconversion rates in high-risk adults, will serve to stimulate growth in the marketplace over the forecast period. Country-specific immunization recommendations and policy implementation will be an essential metric for determining future vaccine uptake in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan) and Canada.

Highlights

Key Questions Answered

- How large an impact will Hexyon and Heplisav have on the HBV vaccine market? What do key opinion leaders think of these vaccines?
- What are the key HBV vaccines for each age segment and country?
- Which HBV vaccines will face adoption challenges in the market? What is the projected uptake of new vaccines, such as Dynavax's Heplisav, over the forecast period?
- The developmental pipeline consists of vaccines that address immunogenicity and coverage rate concerns. Which of these vaccines will attain high sales revenues during 2012-2022 and in which markets?
- What governmental and industry developments are likely to affect the vaccination rates in the markets researched? Which is the largest growth market globally?

Key Findings

- Country-specific immunization recommendations heavily influence HBV vaccine uptake in the pediatric and adult segments of the marketplace.
- The potential impact of Dynavax Technologies' Heplisav on the marketplace will be determined by its level of uptake in at-risk adults targeted for vaccination.
- Major players will leverage their R&D, manufacturing, and distribution networks to maintain their stakes in the market.
- Government endorsements of new and existing vaccines, in particular pediatric combination vaccines and novel adult vaccines, are anticipated to dramatically influence market growth.

Scope

- Overview of hepatitis B virus (HBV), including etiology, general symptoms from infection, and country-specific immunization recommendations and vaccination coverage data.
- Annualized HBV vaccine market revenue, annual cost of vaccination and treatment usage pattern data from 2012 and forecast for ten years to 2022.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the HBV vaccine market.
- Pipeline analysis: comprehensive data split across different phases and emerging trends, specifically Dynavax Technologies' Heplisav and Sanofi Pasteur MSD's Hexyon.
- Analysis of the current and future market competition in the global HBV vaccine market. Insightful review of the key industry and governmental drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the HBV vaccine market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global HBV vaccine market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global HBV vaccine market from 2012-2022.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
4.9.2 Vaccination Coverage
4.9.3 Clinical Practice
5 Competitive Assessment
5.1 Overview
5.2 Strategic Competitor Assessment
5.3 Product Profiles - Monovalent Vaccines
5.3.1 Engerix-B
5.3.2 Recombivax HB
5.3.3 Fendrix
5.3.4 Bimmugen
5.4 Product Profiles - Combination Vaccines
5.4.1 Infanrix Hexa
5.4.2 Pediariix
5.4.3 Hexyon
5.4.4 Comvax
5.4.5 Twinrix
5.4.6 Ambirix
6 Opportunity and Unmet Need
6.1 Overview
6.2 Increased Vaccine Immunogenicity
6.2.1 Unmet Need
6.2.2 Gap Analysis
6.2.3 Opportunity
6.3 Increased Vaccination Coverage Rates
6.3.1 Unmet Need
6.3.2 Gap Analysis
6.3.3 Opportunity
6.4 Increased Patient Awareness
6.4.1 Unmet Need
6.4.2 Gap Analysis
6.4.3 Opportunity
6.5 Improved Physician Education
6.5.1 Unmet Need
6.5.2 Gap Analysis
6.5.3 Opportunity
6.6 More Cost-Effective Vaccines
6.6.1 Unmet Need
6.6.2 Gap Analysis
6.6.3 Opportunity
7 Pipeline Assessment
7.1 Overview
7.2 Clinical Trial Mapping
7.2.1 Clinical Trials by Country
7.2.2 Clinical Trials by Phase and Trial Status
7.3 Promising Vaccines in Late-Stage Clinical Development
7.3.1 Heplisav
7.4 Promising Vaccines in Early-Stage Clinical Development
8 Current and Future Players
8.1 Overview
8.2 Trends in Corporate Strategy
8.3 Company Profiles
8.3.1 GSK
8.3.2 Merck
8.3.3 Sanofi
8.3.4 Kaketsuken
8.3.5 Dynavax Technologies
9 Market Outlook
9.1 Global Markets
9.1.1 Forecast
9.1.2 Drivers and Barriers - Global Issues
9.2 US
9.2.1 Forecast
9.2.2 Key Events
Table 9: Product Profile - Engerix-B
Table 10: Immunogenicity Profile - Engerix-B
Table 11: Safety Profile - Engerix-B
Table 12: Engerix-B SWOT Analysis, 2014
Table 13: Global Sales Forecasts ($m) for Engerix-B, 2012-2022
Table 14: Product Profile - Recombivax HB
Table 15: Immunogenicity Profile - Recombivax HB
Table 16: Safety Profile - Recombivax HB
Table 17: Recombivax HB SWOT Analysis, 2014
Table 18: Global Sales Forecasts ($m) for Recombivax HB, 2012-2022
Table 19: Product Profile - Fendrix
Table 20: Immunogenicity Profile - Fendrix
Table 21: Safety Profile - Fendrix
Table 22: Fendrix SWOT Analysis, 2014
Table 23: Global Sales Forecasts ($m) for Fendrix, 2012-2022
Table 24: Product Profile - Bimmugen
Table 25: Bimmugen SWOT Analysis, 2014
Table 26: Global Sales Forecasts ($m) for Bimmugen, 2012-2022
Table 27: Product Profile - Infanrix Hexa
Table 28: Immunogenicity Profile - Infanrix Hexa
Table 29: Safety Profile - Infanrix Hexa
Table 30: Infanrix Hexa SWOT Analysis, 2014
Table 31: Global Sales Forecasts ($m) for Infanrix Hexa, 2012-2022
Table 32: Product Profile - Pediarix
Table 33: Immunogenicity Profile - Pediarix
Table 34: Safety Profile - Pediarix
Table 35: Pediarix SWOT Analysis, 2014
Table 36: Global Sales Forecasts ($m) for Pediarix, 2012-2022
Table 37: Product Profile - Hexyon
Table 38: Immunogenicity Profile - Hexyon
Table 39: Safety Profile - Hexyon
Table 40: Hexyon SWOT Analysis, 2014
Table 41: Global Sales Forecasts ($m) for Hexyon, 2012-2022
Table 42: Product Profile - Comvax
Table 43: Immunogenicity Profile - Comvax
Table 44: Safety Profile - Comvax
Table 45: Comvax SWOT Analysis, 2014
Table 46: Global Sales Forecasts ($m) for Comvax, 2012-2022
Table 47: Product Profile - Twinrix
Table 48: Immunogenicity Profile - Twinrix
Table 49: Safety Profile - Twinrix
Table 50: Twinrix SWOT Analysis, 2014
Table 51: Global Sales Forecasts ($m) for Twinrix, 2012-2022
Table 52: Product Profile - Ambirix
Table 53: Immunogenicity Profile - Ambirix
Table 54: Safety Profile - Ambirix
Table 55: Ambirix SWOT Analysis, 2014
Table 56: Global Sales Forecasts ($m) for Ambirix, 2012-2022
Table 57: Unmet Need and Opportunity in Prophylactic HBV Vaccines
Table 58: HBV Vaccines - Clinical Trials by Phase and Status, 2014
Table 59: HBV Vaccines - Phase Pipeline, 2014
Table 60: Comparison of Vaccines in Development for HBV, 2014
Table 61: Product Profile - Heplisav
Table 62: Immunogenicity Profile - Heplisav
Table 63: Safety Profile - Heplisav
Table 64: Heplisav SWOT Analysis, 2014
Table 65: Global Sales Forecasts ($m) for Heplisav, 2012-2022
Table 66: Key Companies in the HBV Vaccine Market, 2014
Table 67: GSK's HBV Vaccine Portfolio Assessment, 2014
Table 68: GSK SWOT Analysis, 2014
Table 69: Merck's HBV Vaccine Portfolio Assessment, 2014
Table 70: Merck SWOT Analysis, 2014
Table 71: Sanofi's HBV Vaccine Portfolio Assessment, 2014
Table 72: Sanofi SWOT Analysis, 2014
Table 73: Kaketsuken's HBV Vaccine Portfolio Assessment, 2014
Table 74: Kaketsuken SWOT Analysis, 2014
Table 75: Dynavax Technologies' HBV Vaccine Portfolio Assessment, 2014
Table 76: Dynavax Technologies SWOT Analysis, 2014
Table 77: Global Sales Forecasts ($m) for HBV Vaccines, 2012-2022
Table 78: Global HBV Vaccine Market - Drivers and Barriers, 2014
Table 79: Sales Forecasts ($m) for HBV Vaccines in the United States, 2012-2022
Table 80: Key Events Impacting Sales for HBV Vaccines in the United States, 2014
Table 81: United States HBV Vaccine Market - Drivers and Barriers, 2014
Table 82: Sales Forecasts ($m) for HBV Vaccines in France, 2012-2022
Table 83: Key Events Impacting Sales for HBV Vaccines in France, 2014
Table 84: France HBV Vaccine Market - Drivers and Barriers, 2014
Table 85: Sales Forecasts ($m) for HBV Vaccines in Germany, 2012-2022
Table 86: Key Events Impacting Sales for HBV Vaccines in Germany, 2014
Table 87: Germany HBV Vaccine Market - Drivers and Barriers, 2014
Table 88: Sales Forecasts ($m) for HBV Vaccines in Italy, 2012-2022
Table 89: Key Events Impacting Sales for HBV Vaccines in Italy, 2014
Table 90: Italy HBV Vaccine Market - Drivers and Barriers, 2014
Table 91: Sales Forecasts ($m) for HBV Vaccines in Spain, 2012-2022
Table 92: Key Events Impacting Sales for HBV Vaccines in Spain, 2014
Table 93: Spain HBV Vaccine Market - Drivers and Barriers, 2014
Table 94: Sales Forecasts ($) for HBV Vaccines in the United Kingdom, 2012-2022
Table 95: Key Events Impacting Sales for HBV Vaccines in the United Kingdom, 2014
Table 96: United Kingdom HBV Vaccine Market - Drivers and Barriers, 2014
Table 97: Sales Forecasts ($) for HBV Vaccines in Japan, 2012-2022
Table 98: Japan HBV Vaccine Market - Drivers and Barriers, 2014
Table 99: Sales Forecasts ($) for HBV Vaccines in Canada, 2012-2022
Table 100: Key Events Impacting Sales for HBV Vaccines in Canada, 2014
Table 101: Canada HBV Vaccine Market - Drivers and Barriers, 2014
Table 102: Patient Population(s) Targeted for HBV Vaccination in the Pediatric Market, by Country
Table 103: Patient Population(s) Targeted for HBV Vaccination in the Adult Market, by Country
Table 104: Key Launch Dates
Table 105: High-Prescribing Physicians (non-KOLs) Surveyed, by Country

1.2 List of Figures
Figure 1: HBV Structure and the Recombinant Vaccine Development Process
Figure 2: Routine HBV Vaccination Coverage (%) in the United States
Figure 3: High-Prescriber Estimation of Pediatric HBV Vaccine Patient Share in the United States, 2014
Figure 4: Routine HBV Vaccination Coverage (%) in France
Figure 5: High-Prescriber Estimation of Pediatric HBV Vaccine Patient Share in France, 2014
Figure 6: Routine HBV Vaccination Coverage (%) in Germany
Figure 7: High-Prescriber Estimation of Pediatric HBV Vaccine Patient Share in Germany, 2014
Figure 8: Routine HBV Vaccination Coverage (%) in Italy
Figure 9: High-Prescriber Estimation of Pediatric HBV Patient Share in Italy, 2014
Figure 10: Routine HBV Vaccination Coverage (%) in Spain
Figure 11: High-Prescriber Estimation of Pediatric HBV Vaccine Patient Share in Spain, 2014
Figure 12: High-Prescriber Estimation of Pediatric HBV Vaccine Patient Share in the United Kingdom, 2014
Figure 13: High-Prescriber Estimation of Pediatric HBV Vaccine Patient Share in Japan, 2014
Figure 14: High-Prescriber Estimation of Pediatric HBV Vaccine Patient Share in Canada, 2014
Figure 15: HBV Vaccines - Clinical Trials by Country, 2014
Figure 16: Competitive Assessment of Late-Stage Pipeline Agents and Marketed Products in HBV Vaccines, 2012-2022
Figure 17: Global Sales for HBV Vaccines by Company, 2012-2022
Figure 18: Company Portfolio Gap Analysis in HBV Vaccines, 2012-2022
Figure 19: Global Sales for HBV Vaccines by Country, 2012-2022
Figure 20: Sales for HBV Vaccines in the United States by Vaccine, 2012-2022
Figure 21: Sales for HBV Vaccines in France by Vaccine, 2012-2022
Figure 22: Sales for HBV Vaccines in Germany by Vaccine, 2012-2022
Figure 23: Sales for HBV Vaccines in Italy by Vaccine, 2012-2022
Figure 24: Sales for HBV Vaccines in Spain by Vaccine, 2012-2022
Figure 25: Sales for HBV Vaccines in the United Kingdom by Vaccine, 2012-2022
Figure 26: Sales for HBV Vaccines in Japan by Vaccine, 2012-2022
Figure 27: Sales for HBV Vaccines in Canada by Vaccine, 2012-2022

Ordering:

Order Online - http://www.researchandmarkets.com/reports/2776133/

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

<table>
<thead>
<tr>
<th>Product Name:</th>
<th>PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Global Drug Forecast and Market Analysis to 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>Web Address:</td>
<td><a href="http://www.researchandmarkets.com/reports/2776133/">http://www.researchandmarkets.com/reports/2776133/</a></td>
</tr>
<tr>
<td>Office Code:</td>
<td>SC6JXED</td>
</tr>
</tbody>
</table>

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF)</td>
<td></td>
</tr>
<tr>
<td>Single User:</td>
<td>USD 10995</td>
</tr>
<tr>
<td>Site License:</td>
<td>USD 21990</td>
</tr>
<tr>
<td>Enterprisewide:</td>
<td>USD 32985</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

<table>
<thead>
<tr>
<th>Title:</th>
<th>Mr ☐ Mrs ☐ Dr ☐ Miss ☐ Ms ☐ Prof ☐</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Name:</td>
<td></td>
</tr>
<tr>
<td>Last Name:</td>
<td></td>
</tr>
<tr>
<td>Email Address: *</td>
<td></td>
</tr>
<tr>
<td>Job Title:</td>
<td></td>
</tr>
<tr>
<td>Organisation:</td>
<td></td>
</tr>
<tr>
<td>Address:</td>
<td></td>
</tr>
<tr>
<td>City:</td>
<td></td>
</tr>
<tr>
<td>Postal / Zip Code:</td>
<td></td>
</tr>
<tr>
<td>Country:</td>
<td></td>
</tr>
<tr>
<td>Phone Number:</td>
<td></td>
</tr>
<tr>
<td>Fax Number:</td>
<td></td>
</tr>
</tbody>
</table>

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World